TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells.The mature immune, nervous, and reproductive systems depend on the TAM family of receptors and their ligands, Gas6 and Protein S (PROS1), for the best phagocytosis of apoptotic cells.
Three homologous type I receptor-tyrosine kinases known as TAMs are triggered by PROS1 and GAS6, two endogenous ligands. These ligands can either act as soluble factors to activate TAMs or act as connecting molecules between TAMs and apoptotic cells (ACs) by opsonizing phosphatidylserine (PS) on ACs. Cancer cell survival and proliferation as well as the suppression of anti-tumor immunity have been linked to abnormal TAM expression and activation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V69563 | Anticancer agent 109 | 2097497-16-8 | Anticancer agent 109 (compound 6-15) is an inhibitor (blocker/antagonist) of the Gas6-Axl axis and has tumor suppressor activity. |
|
V69487 | AXL-IN-13 | 2376928-82-2 | AXL-IN-13 is a potent, orally bioactive AXL inhibitor (IC50= 1.6 nM, Kd: 0.26 nM). |
|
V69569 | AXL-IN-14 | 2947506-65-0 | AXL-IN-14 is a potent orally bioactive AXL inhibitor (antagonist) with IC50 of 0.8 nM. |
|
V69571 | AXL-IN-15 | 1954722-22-5 | AXL-IN-15 (cpd391) is a potent Axl inhibitor (antagonist) with Ki and IC50 <1 nM. |
|
V69572 | Axl-IN-3 | 2783991-34-2 | Axl-IN-3 is a specific, orally bioactive AXL kinase inhibitor (antagonist) with IC50 of 41.5 nM. |
|
V69282 | Axl/Mer/CSF1R-IN-1 | 2394874-60-1 | Axl/Mer-IN-1 (Compound 1) is an inhibitor (blocker/antagonist) of Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R with Kds less than 0.1 μM. |
|
V69280 | Axl/Mer/CSF1R-IN-2 | 2394874-63-4 | Axl/Mer/CSF1R-IN-2 (Comp 4) is an inhibitor (blocker/antagonist) of Axl, Mer and CSF1R. |
|
V69570 | AZ14145845 | 2830555-70-7 | AZ14145845 is a selective Mer/Axl type I1/2 dual-specific kinase inhibitor (antagonist) with in vivo efficacy. |
|
V69565 | Batiraxcept (AVB-S6-500) | 2268717-61-7 | Batiraxcept (AVB-S6-500) is a potent and specific AXL inhibitor that is a recombinant fusion protein dimer containing the extracellular domain of human AXL and the human immunoglobulin G1 heavy chain (Fc). |
|
V0639 | Dubermatinib (TP-0903) | 1341200-45-0 | Dubermatinib (formerly also known as TP-0903;TP-0903) is a novel, selective and orally bioavailable inhibitor of the AXL receptor tyrosine kinase with potential antineoplastic activity. |
|
V69567 | Enapotamab (Anti-AXL/UFO Reference Antibody (enapotamab)) | 1912423-61-0 | Enapotamab is an AXL/UFO-related antibody that may be utilized to prepare Bcl-xl inhibitor antibody active molecular conjugates. |
|
V33826 | Glesatinib hydrochloride | 1123838-51-6 | Glesatinib HCl (MGCD265 HCl) is an orally bioactive, potent dual MET/SMO inhibitor. |
|
V0638 | LDC1267 | 1361030-48-9 | LDC1267 (LDC-1267) is a novel, highly potent and selective TAM (Tyro3, Axl and Mer) kinase inhibitor with potential antitumor activity. |
|
V69568 | Mipasetamab uzoptirine (ADCT-601) | 2304799-73-1 | Mipasetamab uzoptirine (ADCT-601) is an AXL-targeting antibody-active molecule conjugate (ADC). |
|
V0595 | NPS-1034 | 1221713-92-3 | NPS-1034 (NPS1034; NPS 1034) is a novel, potent dual inhibitor of the tyrosine kinases Met and Axl with potential antineoplastic activity. |
|
V0635 | Bemcentinib (R428; BGB-324; R-428) | 1037624-75-1 | Bemcentinib (formerly known as BGB324; R428) is a novel, potent and selectiveinhibitor of the RTK (receptor tyrosine kinase) Axl with potential anticancer activity. |
|
V3425 | SGI-7079 | 1239875-86-5 | SGI-7079 (SGI7079) is a novel, potent and selective Axl inhibitor with potential anti-inflammatory and anticancer activities. |
|
V69564 | Tilvestamab (BGB149) | 2226775-26-2 | Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. |
|
V69566 | UNC1062 | 1350549-36-8 | UNC1062 is a MERTK-selective tyrosine kinase inhibitor that reduces the activation of MERTK-mediated downstream signaling, causes apoptosis in culture, reduces colony formation in soft agar, and inhibits melanoma cell invasion. |
|
V0636 | UNC2250 | 1493694-70-4 | UNC2250 (UNC-2250) is a novel, potent and selective Mer inhibitor with potential antitumor activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
